Latest Oncology News

Phase 3 Trial of Pembrolizumab Meets Primary PFS End Point in Endometrial Cancer

February 03, 2023

The phase 3 NRG-GY018 trial of pembrolizumab and standard of care chemotherapy led to a clinically meaningful improvement in progression-free survival vs standard of care alone in endometrial carcinoma regardless of mismatch repair status.

Engaging Oncology Peers in Discussions Around Precision Medicine

February 03, 2023

In an interview with Targeted Oncology™, Manmeet Ahluwalia, MD, discussed the importance of the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium, what to expect from his presentation on brain metastases, and what to expect from presentations by other experts.

Clinical Implications of Recent Advancements in Immunotherapy for NSCLC

February 03, 2023

In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.

NCCN Guidelines Add Neratinib for Patients With Breast Cancer

February 03, 2023

Positive data from 2 phase 2 studies, SUMMIT and MutHER, have led to the addition of neratinib as a monotherapy or in combination to the National Comprehensive Cancer Network Guidelines for patients with breast cancer.